| 124.75 3.01 (2.47%) | 09-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 152.77 |
1-year : | 178.44 |
| Resists | First : | 130.8 |
Second : | 152.77 |
| Pivot price | 125.05  |
|||
| Supports | First : | 122.61 |
Second : | 117.55 |
| MAs | MA(5) : | 122.68 |
MA(20) : | 125.85 |
| MA(100) : | 111.74 |
MA(250) : | 102.99 |
|
| MACD | MACD : | 0.3 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 24.2 |
D(3) : | 14 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 132.6 | Low : | 81.08 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ INCY ] has closed above bottom band by 46.7%. Bollinger Bands are 18.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 125.06 - 125.94 | 125.94 - 126.62 |
| Low: | 119.84 - 120.77 | 120.77 - 121.49 |
| Close: | 123.52 - 124.98 | 124.98 - 126.11 |
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Wed, 16 Sep 2026
Is Incyte (INCY) Undervalued After Ontario Backed MINJUVI Access? - Yahoo Finance
Wed, 16 Sep 2026
INCY: Five late-stage assets and strategic deals position the company for strong post-2030 growth - TradingView
Tue, 15 Sep 2026
Incyte Genomics Inc (INCY) EPS 2025: $6.41, up 4173.3% - Stock Titan
Tue, 15 Sep 2026
Incyte Genomics Inc (INCY) Net Income 2025: $1.3B, up 3846.9% - Stock Titan
Tue, 15 Sep 2026
Incyte (INCY) Stock Could Be 30% Overvalued As MINJUVI Funding Lands - simplywall.st
Tue, 15 Sep 2026
Incyte (INCY) Stock Could Be 30% Overvalued As MINJUVI Funding Lands - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 203 (M) |
| Shares Float | 171 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 103.6 (%) |
| Shares Short | 9,390 (K) |
| Shares Short P.Month | 10,510 (K) |
| EPS | 7.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 31.56 |
| Profit Margin | 27.7 % |
| Operating Margin | 41.9 % |
| Return on Assets (ttm) | 16.8 % |
| Return on Equity (ttm) | 30.6 % |
| Qtrly Rev. Growth | 37.7 % |
| Gross Profit (p.s.) | 15.98 |
| Sales Per Share | 28.71 |
| EBITDA (p.s.) | 9.57 |
| Qtrly Earnings Growth | 37.7 % |
| Operating Cash Flow | 1,980 (M) |
| Levered Free Cash Flow | 1,180 (M) |
| PE Ratio | 15.89 |
| PEG Ratio | 10.7 |
| Price to Book value | 3.95 |
| Price to Sales | 4.34 |
| Price to Cash Flow | 12.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|